These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26268906)

  • 21. Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice.
    Sennino B; Raatschen HJ; Wendland MF; Fu Y; You WK; Shames DM; McDonald DM; Brasch RC
    Magn Reson Med; 2009 Sep; 62(3):616-25. PubMed ID: 19526501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of gadofluorine-M and Gd-DTPA for noninvasive staging of atherosclerotic plaque stability using MRI.
    Ronald JA; Chen Y; Belisle AJ; Hamilton AM; Rogers KA; Hegele RA; Misselwitz B; Rutt BK
    Circ Cardiovasc Imaging; 2009 May; 2(3):226-34. PubMed ID: 19808597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrast-enhanced magnetic resonance angiography with biodegradable (Gd-DTPA)-cystamine copolymers: comparison with MS-325 in a swine model.
    Nguyen TD; Spincemaille P; Vaidya A; Prince MR; Lu ZR; Wang Y
    Mol Pharm; 2006; 3(5):558-65. PubMed ID: 17009855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the maturity and functionality of tumor vasculature by MRI: correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors.
    Baudelet C; Cron GO; Gallez B
    Magn Reson Med; 2006 Nov; 56(5):1041-9. PubMed ID: 16986109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinoma.
    Boschi F; Marzola P; Sandri M; Nicolato E; Galiè M; Fiorini S; Merigo F; Lorusso V; Chaabane L; Sbarbati A
    MAGMA; 2008 May; 21(3):169-76. PubMed ID: 18317830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
    J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography.
    Kiessling F; Krix M; Heilmann M; Vosseler S; Lichy M; Fink C; Farhan N; Kleinschmidt K; Schad L; Fusenig NE; Delorme S
    Invest Radiol; 2003 Aug; 38(8):516-24. PubMed ID: 12874518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids.
    Jackson EF; Esparza-Coss E; Wen X; Ng CS; Daniel SL; Price RE; Rivera B; Charnsangavej C; Gelovani JG; Li C
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):830-8. PubMed ID: 17379450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent.
    Casneuf VF; Delrue L; Van Damme N; Demetter P; Robert P; Corot C; Duyck P; Ceelen W; Boterberg T; Peeters M
    Radiat Res; 2011 Jan; 175(1):10-20. PubMed ID: 21175342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of a biodegradable macromolecular contrast agent in dynamic contrast-enhanced MRI for assessing the efficacy of indocyanine green-enhanced photothermal cancer therapy.
    Feng Y; Emerson L; Jeong EK; Parker DL; Lu ZR
    J Magn Reson Imaging; 2009 Aug; 30(2):401-6. PubMed ID: 19629979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.
    Delrue LJ; Casneuf V; Van Damme N; Blanckaert P; Peeters M; Ceelen WP; Duyck PC
    MAGMA; 2011 Aug; 24(4):225-32. PubMed ID: 21567161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
    Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC
    J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe₃O₄ magnetic nanoparticles for targeted anticancer effects.
    Li M; Neoh KG; Wang R; Zong BY; Tan JY; Kang ET
    Eur J Pharm Sci; 2013 Jan; 48(1-2):111-20. PubMed ID: 23108167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of fraction of hypoxic cells in human tumor xenografts with necrotic regions by dynamic contrast-enhanced MRI.
    Egeland TA; Gaustad JV; Benjaminsen IC; Hedalen K; Mathiesen B; Rofstad EK
    Radiat Res; 2008 Jun; 169(6):689-99. PubMed ID: 18494552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.
    Misri R; Wong NK; Shenoi RA; Lum CM; Chafeeva I; Toth K; Rustum Y; Kizhakkedathu JN; Khan MK
    Nanomedicine; 2015 Oct; 11(7):1785-95. PubMed ID: 25981338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
    Lemasson B; Serduc R; Maisin C; Bouchet A; Coquery N; Robert P; Le Duc G; Troprès I; Rémy C; Barbier EL
    Radiology; 2010 Nov; 257(2):342-52. PubMed ID: 20829544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.